MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) is relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN plus DEX)

被引：0
|
作者：
Siegel, David Samuel DiCapua
Agajanian, Richy
Gaur, Rakesh
Karamiou, Kasra
Kaya, Hakan
Sturniolo, Michael
Ricafort, Rosanna J.
Larkins, Gall
Srinivasan, Shankar
Chopra, Rajosh
Thakurta, Anjan
Nagarwala, Yasir M.
Kruter, Flavio
机构：
[1] John Theurer Canc Ctr, Hackensack, NJ USA
[2] Oncol Inst Hope & Innovat, Downey, CA USA
[3] St Lukes Canc Inst, Kansas City, MO USA
[4] Bay Area Canc Res Grp, Pleasant Hill, CA USA
[5] Canc Care Northwest, Spokane, WA USA
[6] Celgene Corp, Summit, NJ USA
[7] Carroll Reg Canc Ctr, Westminister, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps8627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8627
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Gertz, Morie A.
    Allred, Jacob B.
    Mandrekar, Sumithra J.
    Dispenzieri, Angela
    Zeldenrust, Stephen R.
    Kumar, Shaji
    Greipp, Philip R.
    Lust, John A.
    Russell, Stephen J.
    Buadi, Francis
    Kyle, Robert A.
    Bergsagel, Peter Leif
    Fonseca, Rafael
    Roy, Vivek
    Mikhael, Joseph
    Stewart, A. Keith
    Rajkumar, S. Vincent
    BLOOD, 2008, 112 (11) : 320 - 320
  • [42] A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.
    Mateos, Maria-Victoria
    Blacklock, Hilary
    Schjesvold, Fredrik
    Rocafiguera, Albert Oriol
    Simpson, David
    George, Anupkumar
    Goldschmidt, Hartmut
    Larocca, Alessandra
    Sherbenou, Daniel Wayne
    Avivi, Irit
    Iida, Shinsuke
    Matsumoto, Morio
    Usmani, Saad Zafar
    Jagannath, Sundar
    Rodriguez-Otero, Paula
    Kher, Uma
    Farooqui, Mohammed Z. H.
    Liao, Jason
    Marinello, Patricia
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
    De Miguel, D.
    Gil, A.
    Golbano, N.
    Diaz, M.
    Guillen, H.
    Vazquez, A.
    Pinedo, B.
    HAEMATOLOGICA, 2017, 102 : 790 - 791
  • [44] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.
    Siegel, David
    Schiller, Gary J.
    Song, Kevin W.
    Agajanian, Richy
    Stockerl-Goldstein, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] MM-013: An ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI) including patients (pts) undergoing hemodialysis
    Sonneveld, Pieter
    Heyne, Nils
    Kueenburg, Elisabeth
    Glasmacher, Axel G.
    Kasserra, Claudia
    Rosettanl, Barbara
    Bacon, Pamela Joy
    Welsel, Katja C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan
    Hagiwara, Shotaro
    Okamoto, Shinichiro
    Matsue, Kosei
    Iida, Shinsuke
    Sunami, Kazutaka
    Komeno, Takuya
    Suzuki, Kenshi
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Tobinai, Kensei
    Chou, Takaaki
    Kaneko, Hitomi
    Iwasaki, Hiromi
    Uemura, Chie
    Tamakoshi, Hiromi
    Zaki, Mohamed H.
    Doerr, Thomas
    Kuroda, Yoshiaki
    Ichinohe, Tatsuo
    BLOOD, 2015, 126 (23)
  • [47] Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis
    Zhou, Dao-Bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    BLOOD, 2013, 122 (21)
  • [48] TEST MM-013-POMALIDOMIDE (POM) SECURITY plus DEXAMETHASONE AT LOW DOSE (DEX) IN PATIENTS WITH MULTIPLE MYELOMA IN RELAPSED/REFRACTORY (MMRR) WITH RENAL INSUFFICIENCY
    De la Rubia, J.
    Katja, Weisel C.
    Meletios, Dimopoulos A.
    Niels, Van de Donk W. C. J.
    Ramasamy, K.
    Gamberi, B.
    Streetly, M.
    Offidani, M.
    Bridoux, F.
    Kueenburg, E.
    Lersch, F.
    Rosettani, B.
    Bacon, P.
    Sonneveld, P.
    HAEMATOLOGICA, 2017, 102 : 19 - 19
  • [49] Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome
    Cai, Qian-Qian
    Wang, Chen
    Cao, Xin-Xin
    Cai, Hao
    Zhou, Dao-Bin
    Li, Jian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 325 - 330
  • [50] IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL
    Zhou, D. B.
    Yu, L.
    Du, X.
    Jin, J.
    Cai, Z.
    Chen, F.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Zhang, J.
    Wortman-Vayn, H.
    Mei, J.
    Wang, J.
    Hou, J.
    HAEMATOLOGICA, 2014, 99 : 371 - 371
12345